rethinkTHC Search
Menu
Study breakdown

THC Drug Dronabinol Safely Reduced Agitation in Alzheimer's Patients in Clinical Trial

Randomized Controlled TrialStrong evidence
The takeaway

Dronabinol (synthetic THC) safely and effectively reduced agitation in Alzheimer's patients over 3 weeks, with a medium effect size and no increase in intoxication or cognitive decline.

Geriatric psychiatrists, Alzheimer's caregivers, and anyone interested in cannabinoid therapeutics for dementia.

Effect size 0.53 on agitation with favorable safety

What the researchers found

In a 3-week RCT of 75 Alzheimer's patients, dronabinol decreased agitation significantly more than placebo on the Pittsburgh Agitation Scale (effect size 0.53, p=0.015). The NPI-C agitation/aggression measure showed a trend (effect size 0.36, p=0.094). 84% completed the trial. Dronabinol was not associated with greater intoxication, cognitive decline, or adverse events except somnolence.

Why it matters

Agitation in Alzheimer's is extremely common and distressing, and current treatments have limited effectiveness with serious safety concerns including increased mortality risk. Dronabinol showed clinically meaningful agitation reduction with a favorable safety profile.

The numbers in context

75 participants across 5 sites. PAS decline: -0.74/week between arms (p=0.015, effect size 0.53). NPI-C A/A decline: -1.26 (p=0.094, effect size 0.36). 84% completion rate. Target dose: 10 mg/day. 9% Black, 11% Hispanic. No increase in intoxication, falls, or cognitive decline.

How the study worked

Multicenter (5 sites), 3-week, randomized, parallel, double-blind, placebo-controlled trial. Dronabinol titrated up to 10 mg daily in divided doses. 75 participants meeting criteria for agitation of Alzheimer's disease.

What this study cannot tell us

Only 3 weeks duration. Most participants were on concomitant psychotropics. Moderate sample size. One of two primary outcomes did not reach significance. Long-term safety and efficacy unknown.

How to read the evidence

Well-designed multicenter double-blind RCT with racially diverse sample, published in American Journal of Geriatric Psychiatry. Moderate sample size but rigorous methodology.

When this study was published

2026 publication of trial conducted 2017-2024.

The bigger picture

This is a landmark trial as the first large randomized study of dronabinol for Alzheimer's agitation. The FDA approved pimavanserin for this indication in 2024, but options remain limited. Dronabinol could become an important addition to the treatment toolkit.

Questions still open

  • Would longer treatment show sustained or enhanced benefits? Could dronabinol reduce the need for antipsychotics in Alzheimer's patients? What is the optimal dose for balancing efficacy and somnolence?

Common questions

Can THC help Alzheimer's agitation?
This clinical trial found that dronabinol (synthetic THC) at up to 10 mg/day safely reduced agitation in Alzheimer's patients with a clinically meaningful effect size and no worsening of cognition.
Did patients get "high" from the medication?
No. Dronabinol treatment was not associated with greater intoxication compared to placebo. Somnolence was the only side effect that was more common with the drug.

Read the original research

A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 34(2), 167-179

Citation

Rosenberg, Paul B; Amjad, Halima; Burhanullah, Haroon; Nowrangi, Milap; Vandrey, Ryan; Pierre, Mersania Jn; Outen, John D; Schultz, Meghan; Marano, Christopher; Agronin, Marc; Wilkins, James M; Harper, David; Laffaye, Todd; Reardon, Eilis; Turner, Kathryn; Ozonsi, Rosain; Drury, Mia; Nguyen, Andre; Hasoğlu, Tuna; Cromwell, Julia; Leoutsakos, Jeannie-Marie; Forester, Brent P. (2026). A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 34(2), 167-179. https://doi.org/10.1016/j.jagp.2025.10.011

Explore the wider topic